sthrn labs is launching soon. Browse the catalog, review our COAs, and inquire to order.
GLP-3R
Retatrutide is a triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. It is studied for its potential effects on metabolic regulation and body composition in preclinical research models. For research use only.
Compound information
What is GLP-3R?
Stability information
Research highlights
Triple receptor synergism
Research focusing on the combined binding dynamics and signaling of GLP-1, GIP, and glucagon receptors.
Thermogenic signaling
Investigating the role of glucagon receptor activation in increasing metabolic rate and heat production.
Glucose homeostasis studies
Studies exploring the dual incretin effects on pancreatic beta-cell function and insulin secretion.
Energy balance homeostasis
Exploration of how triple agonists influence satiety signaling and adipose tissue metabolism.
Sources & references
Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled Phase 2 trial
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized Phase 2a trial
All citations link directly to primary literature. sthrn labs does not reproduce, excerpt, or summarize article content.
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
